




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR: Plechaczyk, et al. ATTY DOCKET: 58256-010200
SERIAL NO.: 09/341,894 ART UNIT: 1632
DATE FILED: December 15, 1999 EXAMINER: Voitach, J.
FOR: BIOLOGICAL MATERIALS FOR DATE: September 30, 2005
TREATING A MAMMAL BY ANTIBODY
GENE TRANSFER &
PHARMACEUTICAL COMPOSITION
CONTAINING SAME

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this Application, and any attached papers, is being deposited with the United States Postal Service as "First Class Mail", in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 30, 2005.


Gabriella Fercu

MAIL STOP: IDS

Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR IDS

Dear Sir:

Transmitted herewith for filing in the above-referenced patent application are the following documents:


- ☒ Information Disclosure Statement (2 pgs.);
- ☒ PTO Form 1449 (1 pg.);
- ☒ Copies of Cited References (8 references);
- ☒ Return Postcard

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at telephone (617) 310-6000.

The Commissioner is hereby authorized to charge all fees that may be due, or credit any overpayment to Deposit Account No. 50-2678, Ref. No. 58256-010200. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Dated: September 30, 2005


Chinh H. Pham, Reg. No.: 39,329
Attorney for Applicants

Customer No. 35893
GREENBERG TRAURIG, LLP
One International Place
Boston, Massachusetts 02110
Tel: (617) 310-6000



Attorney Docket No. 58256-010200


FW
1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR:	Piechaczyk, et al.	ATTY. DOCKET:	58256-010200
SERIAL NO.:	09/341,894	ART UNIT:	1632
FILING DATE:	December 15, 1999	EXAMINER:	Woitach, J.
FOR:	BIOLOGICAL MATERIAL FOR TREATING A MAMMAL BY ANTIBODY GENE TRANSFER & PHARMACEUTICAL COMPOSITION CONTAINING SAME	DATE OF DEPOSIT:	September 30, 2005

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "First Class Mail", in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 30, 2005.


Gabriella Fercu

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. A full copy of each cited publication is enclosed. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☒ This Information Disclosure Statement is being submitted after the mailing of an Office Action on the merits on the above-identified application. Therefore, a fee is due for submission of this Information Disclosure Statement, pursuant to 37 C.F.R. § 1.97(c), authorization is hereby given to charge the required fee (\$180) under 37 C.F.R. § 1.197(c) and 37 C.F.R. § 1.17(p) to Deposit Account No. 50-2678.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has

APPLICANTS: **PIECHACZYK, et al.**
U.S.S.N.: **09/341,894**


been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-2678, Reference No. 58256-010200.

Respectfully submitted,


Dated: September 30, 2005



Chinh H. Pham, Reg.: 39,329
Attorney for Applicants
GREENBERG TRAURIG, LLP
One International Place
Boston, Massachusetts 02110
Tel: (617) 310-6000
Fax: (617) 310-6001

bos-fs1\155366v01

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/341,894
	Filing Date	December 15, 2999
	First Named Inventor	PIECHACZYK, et al.
	Group Art Unit	1632
	Examiner Name	Woitach, J.
	Attorney Docket Number	58256-010200

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	A1	Noël, D., Marin, M., Biard-Piechaczyk, M., Mani, J-C and Piechaczyk M, "In vitro and in vivo expression of recombinant antibodies by genetically modified myoblasts, Hum. Gen. Ther., 8:1219-1229, ", (1997).
	A2	Hatzioannou et al., "Retroviral Display of Functional Binding Domains Fused to the Amino Terminus of Influenza Hemagglutinin", Human Gene Therapy, 10:1533-1544, (1999).
	A3	Pelegriin, M., M. Marin, D. Noël, Del Rio, M., R. Saller, J. Stange, S. Mitzner, W. Gunzburg, and M. Piechaczyk, "Systemic delivery of antibodies using cells encapsulated in a matrix of cellulose sulphate", Gene Ther., 5:828-834, (1998).
	A4	Pelegriin, M., Marin, M., Noël, D., Saller, R., Salmons, B. and Piechaczyk, M., "Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies, Hum. Gene Ther., 10:1407-1415, ", (2000b).
	A5	Noël D., Pelegriin M., Marin M., Piechaczyk M., "Neo-organs of skin fibroblasts allow sustained expression of antibodies in mice", Journal Invest Derm, 104:740-745, (2000).
	A6	Noël, D., Dazard, J-E., Pelegriin, M., Jacquet, Ch. And Piechaczyk, M., "Skin as an organ for antibody production", Journal Invest. Derm., 118:288-94, (2002a).
	A7	Noël D., Pelegriin M., Kramer, S., Skander, N., Jacquet, C. and Piechaczyk, M., "A high in vivo monoclonal antibody production upon adenoviral gene transfer can induce a low but non neutralizing anti-idiotypic response", Hum. Gene Ther., 13:1483-1493, (2002b).
	A8	Perez N, Bigey P, Scherman D, Danos O, Piechaczyk M, Pelegriin M., "Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation, Genet Vaccines Ther., 23:2(1):2, (2004).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

bos-srv01\156357v01